Gilead Sciences, INC.: directors' dealings · United States · SEC (Form 4)

About Gilead Sciences, INC.

Gilead Sciences, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker GILD, with its corporate headquarters in Foster City, California, United States. Founded in 1987, Gilead built its reputation in antiviral medicines and has since broadened its strategy into oncology and inflammation. The company’s legacy and current market standing are anchored in virology, especially HIV, while its liver disease franchise and oncology platform have become important contributors to the long-term investment case. ([gilead.com](https://www.gilead.com/contact?utm_source=openai)) From a business-model perspective, Gilead combines high-value specialty pharmaceutical commercialization with a deep R&D engine and a global development, manufacturing, and regulatory footprint. Its main therapeutic areas include HIV, liver disease, oncology, and, increasingly, inflammation. Key marketed products and programs include Biktarvy and Descovy in HIV, Veklury in certain COVID-19-related settings, Trodelvy in oncology, and Yeztugo, which Gilead describes as the first twice-yearly HIV prevention therapy. The company is also advancing next-generation programs, including bictegravir/lenacapavir combinations and a broader pipeline in hematology, cell therapy, and immunology. ([gilead.com](https://www.gilead.com/news/news-details/2026/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results?utm_source=openai)) Gilead’s competitive position is that of a large-cap biotech with durable franchises, strong regulatory moats, and significant commercial execution capabilities. At the same time, it remains exposed to the classic biopharma risks: pricing pressure, reimbursement challenges, and patent or lifecycle risk on mature products. The company operates internationally in more than 35 countries, while maintaining a substantial U.S. industrial and scientific base. Its U.S. footprint includes manufacturing, packaging, labeling, and distribution activities, with Foster City serving as the worldwide headquarters and ongoing investment in domestic research and manufacturing capacity. ([gilead.com](https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel?utm_source=openai)) Recent developments highlight a more expansionary strategic phase. In 2026, Gilead reported full-year 2025 results showing growth in HIV and liver disease sales and announced a quarterly dividend increase. The company also pursued targeted M&A and pipeline expansion, including the announced acquisition of Tubulis and the Arcellx transaction, while the FDA granted priority review for a bictegravir/lenacapavir HIV treatment application. In parallel, Gilead and its partners continued to expand access initiatives for lenacapavir for HIV prevention. Overall, Gilead remains a major U.S. healthcare name on the NASDAQ with a mix of established cash-generating franchises and meaningful pipeline optionality. ([investors.gilead.com](https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx?utm_source=openai))